title: The use of lisdexamfetamine dimesylate for the treatment of ADHD.
abstract: ADHD is a common neurobehavioral disorder characterized by significant impairment in attention, hyperactivity and impulsivity. Symptoms begin in childhood and can persist into adulthood. Current data suggest that abnormal functioning of the prefrontal cortex, cortical and subcortical regions of the brain have roles in ADHD. All currently approved drugs used to treat ADHD enhance dopamine and norepinephrine signals in these regions. Lisdexamfetamine dimesylate (LDX) is a long-acting amphetamine prodrug indicated for the treatment of ADHD and has been shown to be effective in children, adolescents and adults. The prodrug properties of LDX make it a desirable treatment because of its long duration of effect, and low intrasubject and intersubject pharmacokinetic variability, and attenuated response on measures of abuse liability when compared with immediate-release amphetamine. However, LDX is still classified as a controlled substance. In this article, the pharmacokinetic parameters and efficacy and safety of LDX are reviewed.
authors.affiliation: Center for Psychiatry and Behavioral Medicine, Inc., 7351 Prairie Falcon Road, Suite 160, Las Vegas, NV, USA. drann87@aol.com
authors.forename: Ann C
authors.initials: AC
authors.lastname: Childress
authors.forename: Floyd R
authors.initials: FR
authors.lastname: Sallee
mesh_terms: D000293:Adolescent; D000328:Adult; D001289:Attention Deficit Disorder with Hyperactivity / Q000188:drug therapy*; D000697:Central Nervous System Stimulants / Q000493:pharmacokinetics / Q000627:therapeutic use*; D002648:Child; D002986:Clinical Trials as Topic; D003913:Dextroamphetamine / Q000493:pharmacokinetics / Q000627:therapeutic use*; D006801:Humans; D000069478:Lisdexamfetamine Dimesylate
chemical_list: D000697:Central Nervous System Stimulants; D000069478:Lisdexamfetamine Dimesylate; D003913:Dextroamphetamine